文献速递重症综合管理与镇静镇痛

现有抗真菌药物剂量对重症患者是否足够?SAFE-ICU国际多中心药代动力学研究结果

Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units-the SAFE-ICU study.
PubMed 文献 · Intensive Care Med · 2025-02-03
一句话结论国际多中心药代动力学研究显示,重症患者接受治疗时伏立康唑、泊沙康唑、米卡芬净和两性霉素B的PK/PD靶目标达标率偏低,暴露不足持续存在。

该研究为前瞻性、开放标签、国际多中心药代动力学研究,纳入12个国家30个ICU的339例接受唑类、棘白菌素类或多烯类抗真菌药物用于治疗或预防侵袭性真菌病的重症患者。在两次给药间隔内各采三次血,中心实验室用经验证的色谱法测总浓度,非房室法估算药代动力学参数,按预设PK/PD靶目标评估剂量充分性。结果:80.8%为治疗用药,氟康唑最常用(40.7%),治疗最常见指征为腹腔感染(30.7%);预防用药患者靶目标达标率较高(多数药物>80%),而治疗患者中伏立康唑57.1%、泊沙康唑63.2%、米卡芬净64.1%、两性霉素B 41.7%达标率偏低。结论提示不同抗真菌药物达标程度不一,广泛变异和亚治疗暴露持续存在。

要点

  • 治疗用药患者中两性霉素B靶目标达标率仅41.7%,为所报告药物中最低。
  • 治疗用药患者中伏立康唑达标率57.1%、泊沙康唑63.2%、米卡芬净64.1%,均偏低。
  • 预防用药患者靶目标达标率较高,多数药物>80%。
  • 339例中80.8%为治疗用药,氟康唑最常用(40.7%),治疗最常见指征为腹腔感染(30.7%)。
  • 仅45%患者鉴定出真菌,其中仅26%有可用的最低抑菌浓度。

适用人群与场景

  • 12个国家30个ICU中处方唑类、棘白菌素类或多烯类抗真菌药用于侵袭性真菌病治疗或预防的重症患者,共339例。
  • 中位年龄62岁(IQR 51-70),中位APACHE II评分22分(IQR 17-28),男性61%。

诊断标准与关键阈值

  • 剂量充分性按预设PK/PD靶目标评估。

研究设计与关键结果

  • 前瞻性、开放标签、国际多中心药代动力学研究,339例来自12个国家30个ICU。
  • 两次场合采血,每次在单一给药间隔内采三次;总浓度中心实验室用经验证色谱法测定,非房室法估算药代动力学参数。
  • 抗真菌治疗主要用于治疗(80.8%);氟康唑最常用(40.7%);治疗最常见指征为腹腔感染(30.7%)。
  • 45%患者鉴定出真菌,其中仅26%有可用的最低抑菌浓度。
  • 预防用药患者靶目标达标率较高(多数药物>80%)。
  • 治疗用药患者靶目标达标率:伏立康唑57.1%、泊沙康唑63.2%、米卡芬净64.1%、两性霉素B 41.7%。

证据类型、等级与局限

  • 证据类型:前瞻性、开放标签、国际多中心药代动力学研究。
  • 试验注册:ClinicalTrials.gov NCT03136926,2017年4月21日。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为该研究凸显重症患者中不同抗真菌药物靶目标达标程度不一,广泛变异和亚治疗暴露持续存在。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Appropriate antifungal therapy is a major determinant of survival in critically ill patients with invasive fungal disease. We sought to describe whether contemporary dosing of antifungals achieves therapeutic exposures in critically ill patients.

METHODS: In a prospective, open-label, multicenter pharmacokinetic study, intensive care unit (ICU) patients prescribed azoles, echinocandins, or polyene antifungals for treatment or prophylaxis of invasive fungal disease were enrolled. Blood samples were collected on two occasions, with three samples taken during a single dosing interval on each occasion. Total concentrations were centrally measured using validated chromatographic methods. Pharmacokinetic parameters were estimated using noncompartmental methods. Antifungal dosing adequacy was assessed using predefined PK/PD targets.

RESULTS: We included 339 patients from 30 ICUs across 12 countries. Median age 62 (interquartile range [IQR], 51-70) years, median APACHE II score 22 (IQR, 17-28), and 61% males. Antifungal therapy was primarily prescribed for treatment (80.8%). Fluconazole was the most frequently prescribed antifungal (40.7%). The most common indication for treatment was intra-abdominal infection (30.7%). Fungi were identified in 45% of patients, of which only 26% had a minimum inhibitory concentration available. Target attainment was higher for patients receiving prophylaxis (> 80% for most drugs). For patients receiving treatment, low target attainment was noted for voriconazole (57.1%), posaconazole (63.2%), micafungin (64.1%) and amphotericin B (41.7%).

CONCLUSION: This study highlights the varying degrees of target attainment across antifungal agents in critically ill patients. While a significant proportion of patients achieved the predefined PK/PD targets, wide variability and subtherapeutic exposures persist.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03136926, 2017-04-21.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Roberts JA, Sime FB, Lipman J, et al. Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units-the SAFE-ICU study. Intensive Care Med. 2025. PMID: 39899034. doi:10.1007/s00134-025-07793-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。